Please login to the form below

Not currently logged in

Stallergenes appoints Christian Chavy CEO

He will replace Roberto Gradnik at the end of this month

Christian Chavy has been appointed CEO of French biopharmaceutical company Stallergenes and will take over from Roberto Gradnik at the end of this month.  

Chavy has worked for the ARES Life Science healthcare investment fund since 2010 and prior to that he served as president of global operations for Actelion Pharmaceuticals.  

Before joining Actelion he was vice president of Serono's reproductive medicine strategic unit and chairman of the company's French subsidiary.

Stallergenes said Chavy's appointment would enable it to “pursue its strategy” and to its work in promising immunotherapy markets – the US in particular.  

Meanwhile Gradnick, who joined Stallergenes in October 2011 as deputy CEO before taking up the post of CEO three months later, will provide consultancy services to the board of directors during a four-month transitional period.

7th March 2014

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...